What are the earliest clinical clues that suggest nephropathic cystinosis in an infant?

Poor weight gain, excessive thirst, frequent urination, and a milky or cloudy appearance of the urine are early red flags. A slit‑lamp eye exam revealing corneal crystals and a blood test for low serum phosphate can support the diagnosis.

What routine eye care is recommended for patients with cystinosis to prevent progression to blindness?

Regular ophthalmology visits (every 3–6 months) with slit‑lamp exams, and the use of protective eyewear or sunglasses to shield from light, help manage photophobia and monitor crystal buildup.

When is a kidney transplant considered for a child with cystinosis, and what factors influence the timing?

Transplant is typically considered when serum creatinine rises above 1.5 mg/dL or when the child develops end‑stage renal disease. Early referral to a pediatric transplant center, assessment of growth status, and management of cysteamine therapy all influence the optimal timing.===

How does cysteamine eye drop therapy help, and what should parents expect in terms of side effects and adherence?

Cysteamine dissolves cystine crystals in the cornea, reducing pain and photophobia. Drops are usually used 4–6 times daily; common side effects include eye irritation, a bitter taste, and mild redness. Consistent use is essential to prevent vision loss.

Cystinosis

Cystinosis is a rare genetic condition characterized by the accumulation of the amino acid cystine, which forms crystals that damage organs and tissues, particularly the kidneys and eyes. Inherited in an autosomal recessive pattern, it presents in three distinct forms ranging in severity from infancy to adulthood.

Overview

Cystinosis is a condition characterized by the accumulation of the amino acid cystine (a building block of proteins) within cells. Excess cystine damages cells and often forms crystals that can build up and cause problems in many organs and tissues. The kidneys and eyes are especially vulnerable to damage; the muscles, thyroid, pancreas, and testes may also be affected.

Types of Cystinosis

There are three distinct types of cystinosis. In order of decreasing severity, they are nephropathic cystinosis, intermediate cystinosis, and non-nephropathic or ocular cystinosis.

Nephropathic Cystinosis

Nephropathic cystinosis begins in infancy, causing poor growth and a particular type of kidney damage called renal Fanconi syndrome. In this syndrome, certain molecules that should be reabsorbed into the bloodstream are instead eliminated in the urine. This loss of important minerals, salts, fluids, and other nutrients impairs growth and may result in soft, bowed bones (hypophosphatemic rickets), especially in the legs.

The nutrient imbalances in the body lead to:

Increased urination
Thirst
Dehydration
Abnormally acidic blood (acidosis)

By about the age of 2, cystine crystals may be present in the clear covering of the eye (cornea). The buildup of these crystals in the eye causes pain and an increased sensitivity to light (photophobia). Untreated children will experience complete kidney failure by about the age of 10. Other signs and symptoms that may occur in untreated people, especially after adolescence, include muscle deterioration, blindness, inability to swallow, diabetes, thyroid and nervous system problems, and an inability to father children (infertility) in affected men.

Intermediate Cystinosis

The signs and symptoms of intermediate cystinosis are the same as nephropathic cystinosis, but they occur at a later age, typically becoming apparent in adolescence. Malfunctioning kidneys and corneal crystals are the main initial features of this disorder. If intermediate cystinosis is left untreated, complete kidney failure will occur, usually in the late teens to mid-twenties.

Non-nephropathic or Ocular Cystinosis

People with non-nephropathic or ocular cystinosis typically experience photophobia due to cystine crystals in the cornea, but usually do not develop kidney malfunction or most of the other signs and symptoms of cystinosis. Due to the absence of severe symptoms, the age at which this form of cystinosis is diagnosed varies widely.

Frequency

Cystinosis affects approximately 1 in 100,000 to 200,000 newborns worldwide. The incidence is higher in the province of Brittany, France, where the disorder affects 1 in 26,000 individuals.

Causes

All three types of cystinosis are caused by mutations in the CTNS gene. Mutations in this gene lead to a deficiency of a transporter protein called cystinosin.

Within cells, this protein normally moves cystine out of the lysosomes, which are compartments in the cell that digest and recycle materials. When cystinosin is defective or missing, cystine accumulates and forms crystals in the lysosomes. The buildup of cystine damages cells in the kidneys and eyes and may also affect other organs.

Inheritance

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Other Names for This Condition

Cystine storage disease

Additional Information & Resources

Genetic Testing Information

Genetic Testing Registry: Cystinosis

Genetic and Rare Diseases Information Center

Cystinosis

Patient Support and Advocacy Resources

National Organization for Rare Disorders (NORD)

Clinical Trials

ClinicalTrials.gov

Catalog of Genes and Diseases from OMIM

CYSTINOSIS, ADULT NONNEPHROPATHIC
CYSTINOSIS, LATE-ONSET JUVENILE OR ADOLESCENT NEPHROPATHIC TYPE
CYSTINOSIS, NEPHROPATHIC; CTNS

Scientific Articles on PubMed

PubMed

References

Delgado G, Schatz A, Nichols S, Appelbaum M, Trauner D. Behavioral profiles of children with infantile nephropathic cystinosis. Dev Med Child Neurol. 2005 Jun;47(6):403-7.
Gahl WA, Thoene JG, Schneider JA. Cystinosis. N Engl J Med. 2002 Jul 11;347(2):111-21.
Kalatzis V, Antignac C. New aspects of the pathogenesis of cystinosis. Pediatr Nephrol. 2003 Mar;18(3):207-15.
Kleta R, Gahl WA. Cystinosis: antibodies and healthy bodies. J Am Soc Nephrol. 2002 Aug;13(8):2189-91.
Kleta R, Gahl WA. Pharmacological treatment of nephropathic cystinosis with cysteamine. Expert Opin Pharmacother. 2004 Nov;5(11):2255-62.
Kleta R, Kaskel F, Dohil R, Goodyer P, Guay-Woodford LM, Harms E, Ingelfinger JR, Koch VH, Langman CB, Leonard MB, Mannon RB, Sarwal M, Schneider JA, Skovby F, Sonies BC, Thoene JG, Trauner DA, Gahl WA; NIH Office of Rare Diseases. First NIH/Office of Rare Diseases Conference on Cystinosis: past, present, and future. Pediatr Nephrol. 2005 Apr;20(4):452-4.
Nesterova G, Gahl W. Nephropathic cystinosis: late complications of a multisystemic disease. Pediatr Nephrol. 2008 Jun;23(6):863-78.
Nesterova G, Gahl WA. Cystinosis: the evolution of a treatable disease. Pediatr Nephrol. 2013 Jan;28(1):51-9.
Servais A, Moriniere V, Grunfeld JP, Noel LH, Goujon JM, Chadefaux-Vekemans B, Antignac C. Late-onset nephropathic cystinosis: clinical presentation, outcome, and genotyping. Clin J Am Soc Nephrol. 2008 Jan;3(1):27-35.
Sonies BC, Almajid P, Kleta R, Bernardini I, Gahl WA. Swallowing dysfunction in 101 patients with nephropathic cystinosis: benefit of long-term cysteamine therapy. Medicine (Baltimore). 2005 May;84(3):137-146.
Tsilou E, Zhou M, Gahl W, Sieving PC, Chan CC. Ophthalmic manifestations and histopathology of infantile nephropathic cystinosis: report of a case and review of the literature. Surv Ophthalmol. 2007 Jan-Feb;52(1):97-105.